Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1/2 1

Status

Completed 2Recruiting 1

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Conditions

Glioma 4Glioblastoma 4Astrocytoma 3Neoplasms 2Lung Neoplasms 2Leukemia, Lymphocytic, Chronic, B-Cell 2Epstein-Barr Virus Infections 2Breast Neoplasms 2Wilms Tumor 1Triple Negative Breast Neoplasms 1Testicular Neoplasms 1Sezary Syndrome 1Recurrence 1Primary Myelofibrosis 1Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Pleural Effusion, Malignant 1Pdgfra-Associated Chronic Eosinophilic Leukemia 1Pancreatic Neoplasms 1Ovarian Neoplasms 1Neuroblastoma 1Myeloproliferative Disorders 1Mycosis Fungoides 1Multiple Myeloma 1Mesothelioma 1Lymphoma, T-Cell, Cutaneous 1Lymphoma, Non-Hodgkin 1Lymphoma, Mantle-Cell 1Lymphoma, Large-Cell, Immunoblastic 1Lymphoma, Large B-Cell, Diffuse 1Lymphoma, Follicular 1

Interventions

Rituximab 4Valganciclovir 2Valacyclovir 2Carboplatin 2Acyclovir 2valomaciclovir 1threonic acid 1otelixizumab 1cc-486 1Zidovudine 1Vincristine 1Vaccines 1Tomography, X-Ray Computed 1Prednisone 1Polymerase Chain Reaction 1Methotrexate 1Matrix-M 1Magnesium Sulfate 1MVA vaccine 1Leucovorin 1Kidney Transplantation 1Interferons 1In Situ Hybridization 1Immunohistochemistry 1Granulocyte Colony-Stimulating Factor 1Gene-Eden-VIR 1Gastrectomy 1Flow Cytometry 1Filgrastim 1Etoposide 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Completed × Epstein-Barr Virus Infections × Valacyclovir × Clear all
NCT01972035 2022-04-12

ValGanciclovir Versus ValAcyclovir for Viral Prophylaxis in Kidney Transplantation

University of Minnesota

Phase 2 Completed
137 enrolled 8 charts

Cytomegalovirus Infections, Epstein-Barr Virus Infections

NCT00274404 2011-10-27

Controlled Trial of Valacyclovir in Infectious Mononucleosis

University of Minnesota

Phase 1/2 Completed
20 enrolled

Infectious Mononucleosis, Epstein-Barr Virus Infections

Data powered by HemOnc (CC BY 4.0) Colophon âš¡